{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T01:59:36Z","timestamp":1649210376176},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2011]]},"DOI":"10.2169\/naika.100.432","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T23:10:31Z","timestamp":1365549031000},"page":"432-440","source":"Crossref","is-referenced-by-count":0,"title":["3. New Antihypertensive Drugs Including Angiotensin II Type 2 Receptor Agonist."],"prefix":"10.2169","volume":"100","author":[{"given":"Masaki","family":"Mogi","sequence":"first","affiliation":[{"name":"Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Wan Y, et al: Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47: 5995-6008, 2004.","DOI":"10.1021\/jm049715t"},{"key":"2","unstructured":"2) Wallinder C: Design, Synthesis and Biological Evaluation of Selective Nonpeptide AT2 Receptor Agonists and Antagonists. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 78: 2008."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Wallinder C, et al: Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem 16: 6841-6849, 2008.","DOI":"10.1016\/j.bmc.2008.05.066"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kaschina E, et al: Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532, 2008.","DOI":"10.1161\/CIRCULATIONAHA.108.784868"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gelosa P, et al: Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 27: 2444-2451, 2009.","DOI":"10.1097\/HJH.0b013e3283311ba1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Rompe F, et al: Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55: 924-931.","DOI":"10.1161\/HYPERTENSIONAHA.109.147843"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Bosnyak S, et al: Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 159: 709-716.","DOI":"10.1111\/j.1476-5381.2009.00575.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mogi M, et al: Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Hypertension 48: 141-148, 2006.","DOI":"10.1161\/01.HYP.0000229648.67883.f9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Vervoort VS, et al: AGTR2 mutations in X-linked mental retardation. Science 296: 2401-2403, 2002.","DOI":"10.1126\/science.1072191"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Fiebeler A, et al: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111: 3087-3094, 2005.","DOI":"10.1161\/CIRCULATIONAHA.104.521625"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Lea WB, et al: Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 75: 936-944, 2009.","DOI":"10.1038\/ki.2009.9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Weber MA, et al: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1423-1431, 2009.","DOI":"10.1016\/S0140-6736(09)61500-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Packer M, et al: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106: 920-926, 2002.","DOI":"10.1161\/01.CIR.0000029801.86489.50"},{"key":"14","unstructured":"14) Tabrizchi R: Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs 2: 1414-1422, 2001."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ruilope LM, et al: Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375: 1255-1266, 2010.","DOI":"10.1016\/S0140-6736(09)61966-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Munzel T, Gori T: Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 54: 1491-1499, 2009.","DOI":"10.1016\/j.jacc.2009.05.066"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Paulis L, Unger T: Novel therapeutic targets for hypertension. Nat Rev Cardiol 7: 431-441.","DOI":"10.1038\/nrcardio.2010.85"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Iwanaga Y, et al: A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. FASEB J 18: 587-588, 2004.","DOI":"10.1096\/fj.03-0872fje"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Li YQ, et al: WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats. Eur J Pharmacol 577: 100-108, 2007.","DOI":"10.1016\/j.ejphar.2007.08.008"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Breschi MC, et al: New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties. J Med Chem 49: 2628-2639, 2006.","DOI":"10.1021\/jm0600186"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/100\/2\/100_432\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T11:58:38Z","timestamp":1644753518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/100\/2\/100_432\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.100.432","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}